Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Lab-Grown skin patch could mend wounds for rare blistering disease patients

NCT ID NCT07193134

First seen Nov 01, 2025 · Last updated May 18, 2026 · Updated 32 times

Summary

This early-stage trial tests a new skin graft made from a patient's own cells, genetically modified to produce a missing protein that helps skin stay attached. The graft is designed to be permanent and aims to heal wounds in people with recessive dystrophic epidermolysis bullosa (RDEB), a severe genetic blistering condition. Up to 9 participants aged 7 and older will be monitored for safety and wound healing over 12 months.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for RDEB are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • The Hospital for Sick Children (SickKids)

    RECRUITING

    Toronto, Ontario, M5G 1E8, Canada

    Contact

    Contact Phone: •••-•••-•••• Email: •••••@•••••

    Contact Phone: •••-•••-•••• Email: •••••@•••••

Conditions

Explore the condition pages connected to this study.